Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INSR | P06213 | 4/20 | 0.54 |
| ▸ | IGF1R | P08069 | 14/20 | 0.53 |
| ▸ | CDK19 | Q9BWU1 | 4/20 | 0.51 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.51 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.50 |
| ▸ | PAK4 | O96013 | 2/20 | 0.50 |
| ▸ | LCK | P06239 | 2/20 | 0.50 |
| ▸ | FYN | P06241 | 2/20 | 0.50 |
| ▸ | CSF1R | P07333 | 2/20 | 0.50 |
| ▸ | RET | P07949 | 2/20 | 0.50 |
| ▸ | MET | P08581 | 2/20 | 0.50 |
| ▸ | ROS1 | P08922 | 2/20 | 0.50 |
| ▸ | FLT1 | P17948 | 2/20 | 0.50 |
| ▸ | KDR | P35968 | 2/20 | 0.50 |
| ▸ | BTK | Q06187 | 2/20 | 0.50 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.50 |
| ▸ | STK3 | Q13188 | 2/20 | 0.50 |
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3762493 | 0.95 | INSR (0.58) | INSRIGF1RCDK19ALKPRKD3 | |
| SCHEMBL3767817 | 0.94 | IGF1R (0.56) | INSRIGF1RCDK19ALKPRKD3 | |
| SCHEMBL3725890 | 0.87 | CDK19 (0.64) | INSRIGF1RCDK19ALKPRKD3 | |
| SCHEMBL3766723 | 0.87 | IGF1R (0.55) | INSRIGF1RCDK19ALKPRKD3 | |
| SCHEMBL3762589 | 0.84 | CDK19 (0.72) | INSRIGF1RCDK19ALKPRKD3 | |
| SCHEMBL3760452 | 0.84 | CDK19 (0.65) | INSRIGF1RCDK19ALKPRKD3 | |
| SCHEMBL3764567 | 0.84 | EGFR (0.50) | INSRIGF1REGFRERBB2 | |
| SCHEMBL3726447 | 0.82 | IGF1R (0.50) | INSRIGF1RCDK19ALKPRKD3 | |
| SCHEMBL3761708 | 0.82 | CDK19 (0.53) | INSRIGF1RCDK19ALKPRKD3 | |
| SCHEMBL3761942 | 0.82 | EGFR (0.49) | INSRIGF1RCDK19ALKPRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2435436-B1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBVIE INC (US) | 2014-07-30 | — | — | EP | claimed |
| US-8354422-B2 | Pyrimidine inhibitors of kinase activity | ABBOTT LABORATORIES INC. (US) | 2013-01-15 | — | — | US | claimed |
| WO-2010138576-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | claimed |
| US-20100305126-A1 | Pyrimidine Inhibitors of Kinase Activity | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | claimed |
| EP-2435436-B1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBVIE INC (US) | 2014-07-30 | — | — | EP | disclosed |
| US-8354422-B2 | Pyrimidine inhibitors of kinase activity | ABBOTT LABORATORIES INC. (US) | 2013-01-15 | — | — | US | disclosed |
| WO-2010138576-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305126-A1 | Pyrimidine Inhibitors of Kinase Activity | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305126-A1 | Pyrimidine Inhibitors of Kinase Activity | IGF1R, CDK2, TK1 | INSR 37/4885IGF1R 1/4885CDK19 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.